A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India

Vaccine Treatment for HIV-Infection

NCT00108654 ·Status: COMPLETED ·Phase: PHASE1

Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients

NCT00488995 ·Status: WITHDRAWN ·Phase: PHASE2

An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease

NCT00002166 ·Status: COMPLETED ·Phase: PHASE3

The Safety and Effectiveness of (+)-Calanolide A in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

NCT00005120 ·Status: UNKNOWN ·Phase: PHASE1

Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption

NCT02463227 ·Status: COMPLETED ·Phase: PHASE1

Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection

NCT00709605 ·Status: COMPLETED ·Phase: PHASE1

Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults

NCT00119873 ·Status: COMPLETED ·Phase: PHASE1

Advancing Dignity, Health, and Optimism in Connection With Long Acting Injectables

NCT05208541 ·Status: RECRUITING

An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml

NCT00002172 ·Status: COMPLETED ·Phase: NA

A Clinical Trial to Evaluate the Safety and Immunogenicity of a Prophylactic HIV Vaccine Candidate

NCT05863585 ·Status: UNKNOWN ·Phase: PHASE1

Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)

NCT00350623 ·Status: TERMINATED ·Phase: PHASE2

The Safety and Effectiveness of Human Monoclonal Antibody, F105, in the Treatment of HIV

NCT00001105 ·Status: COMPLETED ·Phase: PHASE1

Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults

NCT02178800 ·Status: COMPLETED ·Phase: PHASE2

Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART

NCT01627678 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults

NCT00472719 ·Status: COMPLETED ·Phase: PHASE1

Safety and Tolerability of AAV8 Delivery of a Broadly Neutralizing Antibody in Adults Living With HIV: a Phase 1, Dose-escalation Trial

NCT03374202 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Safety and Efficacy of an Antibody to CCR5 in Individuals With HIV Who Are Not Currently on Antiretroviral Therapy

NCT00114699 ·Status: COMPLETED ·Phase: PHASE1

Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)

NCT05115838 ·Status: WITHDRAWN ·Phase: PHASE2

Pharmacokinetics and Safety of SAR441236

NCT03705169 ·Status: TERMINATED ·Phase: PHASE1

A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)

NCT00764946 ·Status: COMPLETED ·Phase: PHASE3

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706

NCT06665646 ·Status: RECRUITING ·Phase: PHASE1

An Antiretroviral Treatment Interruption (ATI) Study to Evaluate the Impact of Genetically Modified Autologous Cells (AGT103-T) to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy

NCT05540964 ·Status: UNKNOWN

REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study

NCT02366026 ·Status: UNKNOWN ·Phase: PHASE3

Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3

NCT00000756 ·Status: COMPLETED ·Phase: PHASE1

Safety and Effectiveness of Immunotherapy With Autologous HIV-Specific CD8 Cells in HIV Infected Adults

NCT00110578 ·Status: COMPLETED ·Phase: PHASE1